Key facts
| Price (PPV) | 36,100 MAD |
|---|---|
| Dispensing status | Schedule A — prescription only |
| Composition (DCI) | criotinib |
| Class | Antineoplastic agents |
| ATC code | L01XE16 |
| Manufacturer | PFIZER MAROC |
| Presentation | Boite de 60 |
| Nature | Médicament |
| Hospital price | 35,400 MAD |
| Data collected on | 9/8/2026 |
Indications
Xalkori est indiqué en première ligne de traitement des patients adultes ayant un cancer du poumon non à petites cellules (CPNPC) anaplastic lymphoma kinase (ALK) positif et avancé. XALKORI® est indiqué dans le traitement des patients adultes ayant reçu au moins un traitement antérieur pour un cancer du poumon non à petites cellules (CPNPC) anaplastic lymphoma kinase (ALK)-positif et avancé. XALKORI® est indiqué dans le traitement des patients adultes ayant un cancer du poumon non à petites cellules (CPNPC) ROS1 (Proto-Oncogene 1, Receptor Tyrosine Kinase)-positif et avancé.
Find an open pharmacy
On-call pharmacies near you
About Xalkori 250 mg
Xalkori 250 mg belongs to the antineoplastic agents therapeutic class. In Morocco, this drug is marketed by PFIZER MAROC and is among the pharmaceutical specialties referenced by the Ministry of Health.
For any question about the use, effects, or drug interactions of Xalkori 250 mg, consult your doctor or pharmacist. This information is provided for educational purposes and does not replace medical advice.
Frequently Asked Questions about Xalkori 250 mg
Answers to common questions from Moroccan patients about this drug.